Skip to navigation Skip to content

Paroxysmal nocturnal haemoglobinuria (PNH) Program in Pharmaceutical Benefits Scheme (PBS) 012-22022230

Expand/Collapse all sectionsExpand all


For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

On this page:

Paroxysmal nocturnal haemoglobinuria (PNH) C5 inhibitor - eculizumab and ravulizumab quick reference

Paroxysmal nocturnal haemoglobinuria (PNH) - pegcetacoplan quick reference

Paroxysmal nocturnal haemoglobinuria (PNH) C5 inhibitor - eculizumab and ravulizumab quick reference

Table 1

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial 1

induction

PB327 form

Written

S100:

eculizumab

ravulizumab

No

OPA

Must be treated by a:

  • haematologist
  • non-specialist physician in consultation with a haematologist

No

Initial 2 - switching from LSDP-funded eculizumab -(induction dose)

PB327 form

Written

S100:

ravulizumab

No

OPA

Must be treated by a:

  • haematologist
  • non-specialist physician in consultation with a haematologist

No

Return - from PBS-subsidised eculizumab -(induction doses)

PB327 form

Written

S100:

ravulizumab

 

No

OPA

Must be treated by a:

  • haematologist
  • non-specialist physician in consultation with a haematologist

No

Return - from PBS-subsidised pegcetacoplan (induction doses)

PB327 form

Written

S100:

ravulizumab

No

OPA

Must be treated by a:

  • haematologist
  • non-specialist physician in consultation with a haematologist

No

Initial switching from PBS -subsidised ravulizumab for pregnancy

PB327 form

Written

S100:

eculizumab

No

OPA

Must be treated by a:

  • haematologist
  • non-specialist physician in consultation with a haematologist

No

Initial - switching from PBS-subsidised pegcetacoplan for pregnancy (induction doses)

PB327 form

Written

S100:

eculizumab

No

OPA

Must be treated by a:

  • haematologist
  • non-specialist physician in consultation with a haematologist

No

Return - from PBS-subsidised pegcetacoplan (induction doses)

PB327 form

Written

S100:

eculizumab

No

OPA

Must be treated by a:

  • haematologist
  • non-specialist physician in consultation with a haematologist

No

Balance of Supply (BOS) transition from non-PBS during induction

PB327 form

Written

S100:

eculizumab

No

OPA

Must be treated by a:

  • haematologist
  • non-specialist physician in consultation with a haematologist

No

Grandfather - transition from non-PBS

PB329 form

Written

S100:

eculizumab

ravulizumab

 

No

OPA

Must be treated by a:

  • haematologist
  • non-specialist physician in consultation with a haematologist

No

Grandfather - transition from LSDP-funded eculizumab

PB329 form

Written

S100:

eculizumab

No

OPA

Must be treated by a:

  • haematologist
  • non-specialist physician in consultation with a haematologist

No

First continuing

or

Subsequent continuing

PB328 form

Written

S100:

eculizumab

ravulizumab

No

OPA

Must be treated by a:

  • haematologist
  • non-specialist physician in consultation with a haematologist

No

Paroxysmal nocturnal haemoglobinuria (PNH) - pegcetacoplan quick reference

Table 2

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

PB343 form

Written

S100:

pegcetacoplan

No

OPA

Must be treated by a:

  • haematologist
  • non-specialist physician in consultation with a haematologist

No

Return

PB344 form

Written

S100:

pegcetacoplan

No

OPA

Must be treated by a:

  • haematologist
  • non-specialist physician in consultation with a haematologist

No

First continuing

or

Subsequent continuing

PB344 form

Written

S100:

pegcetacoplan

No

OPA

Must be treated by a:

  • haematologist
  • non-specialist physician in consultation with a haematologist

No